Get the Stockscreener App
5.55
2.40%
0.13
After Hours:
5.55
Purple Biotech Ltd Adr stock is traded at $5.55, with a volume of 20,388.
It is up +2.40% in the last 24 hours and down -43.25% over the past month.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.
See More
Previous Close:
$5.42
Open:
$5.4
24h Volume:
20,388
Relative Volume:
0.92
Market Cap:
$8.69M
Revenue:
-
Net Income/Loss:
$-19.88M
P/E Ratio:
-5.0455
EPS:
-1.1
Net Cash Flow:
$-19.93M
1W Performance:
-14.48%
1M Performance:
-43.25%
6M Performance:
-58.58%
1Y Performance:
-76.68%
1-Day Range:
$5.32
$5.67
1-Week Range:
$5.13
$6.7199
52-Week Range:
$5.13
$36.00
Purple Biotech Ltd Adr Stock (PPBT) Company Profile
Purple Biotech Ltd Adr Stock (PPBT) Latest News
PPBT stock touches 52-week low at $5.89 amid market challenges - Investing.com
Purple Biotech price target raised by H.C. Wainwright, maintains Buy rating - Investing.com India
Purple Biotech price target raised by H.C. Wainwright, maintains Buy rating - Investing.com
Ratio Review: Analyzing Purple Biotech Ltd ADR (PPBT)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire Inc.
What Makes Purple Biotech (PPBT) a New Buy Stock - Yahoo Finance
Purple Biotech stock target cut on trial cohort issue - Investing.com
Purple Biotech granted Nasdaq compliance extension - Investing.com
95 Promising Stocks You Can Currently Buy for Less Than $5 Per Share - GOBankingRates
Purple Biotech stock retains Buy rating from H.C. Wainwright - Investing.com
Purple Biotech Ltd ADR (PPBT) Stock Behavior Isn't As Predictable As You Think – Stocks Register - Stocks Register
Financial Fitness Check: Examining Purple Biotech Ltd ADR (PPBT)’s Key Ratios - The Dwinnex
You might want to take a look at Purple Biotech Ltd ADR (PPBT) now – Sete News - SETE News
Why Purple Biotech (PPBT) Shares Are Trading Lower - Quantisnow
The Significance of Moving Averages in Purple Biotech Ltd ADR Inc. (PPBT) Price Performance - The InvestChronicle
Why Purple Biotech (PPBT) Shares Are Trading Lower - TradingView
Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds - GlobeNewswire Inc.
A closer look at Purple Biotech Ltd ADR (PPBT)'s stock price trends – US Post News - US Post News
Why Purple Biotech (PPBT) Shares Are Trading Lower - Benzinga
Manulife Financial Corp. [MFC] gain 19.91% so far this year. What now? – The DBT News - The DBT News
Purple Biotech Ltd ADR Inc. (PPBT) Price Performance: The Role of Volume and Liquidity - The InvestChronicle
Analyzing PPBT's price-to-book ratio for the last quarter – US Post News - US Post News
Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit - GlobeNewswire Inc.
Purple Biotech Ltd ADR (PPBT) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Insider's View: Deciphering Purple Biotech Ltd ADR (PPBT)'s Financial Health Through Ratios – DWinneX - The Dwinnex
Purple Biotech shares target cut by Jones Trading on interim Ph2 data - Investing.com India
Purple Biotech shares target cut by Jones Trading on interim Ph2 data By Investing.com - Investing.com
Purple Biotech shares target cut by Jones Trading on interim Ph2 data - Investing.com
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer - GlobeNewswire Inc.
A stock that deserves closer examination: Purple Biotech Ltd ADR (PPBT) – US Post News - US Post News
Purple Biotech Ltd ADR (PPBT) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Purple Biotech Reports First Quarter 2024 Financial Results - GlobeNewswire Inc.
Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisher - Yahoo Finance
7 High-Potential Penny Stocks in the Biotech Sector - InvestorPlace
A new, genetically modified purple tomato may hit the grocery market stands - CNN
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday - The Globe and Mail
The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts - Benzinga
The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues - Benzinga
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Markets Insider
Purple Biotech (PPBT) Stock Price, News & Analysis - MarketBeat
Purple Biotech Ltd Adr Stock (PPBT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):